Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Initial and Subsequent Response to Pneumococcal Polysaccharide and Protein-Conjugate Vaccines Administered Sequentially to Adults Who Have Recovered from Pneumococcal Pneumonia

Daniel M. Musher, Adriana M. Rueda, Moon H. Nahm, Edward A. Graviss and Maria C. Rodriguez-Barradas
The Journal of Infectious Diseases
Vol. 198, No. 7 (Oct. 1, 2008), pp. 1019-1027
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/40254229
Page Count: 9
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Initial and Subsequent Response to Pneumococcal Polysaccharide and Protein-Conjugate Vaccines Administered Sequentially to Adults Who Have Recovered from Pneumococcal Pneumonia
Preview not available

Abstract

Background. Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at high risk for pneumococcal disease. We studied PPV, protein-conjugate pneumococcal vaccine (PCV), and immunologic "priming" with PCV followed by "boosting" with PPV in adults who had recovered from pneumococcal pneumonia. Methods. Subjects received PPV followed by PCV 6 months later, or vice versa. The levels of IgG to capsular polysaccharide and opsonophagocytic killing activity (OPK) were studied at baseline and at 4–8 weeks and 6 months after each vaccination. Results. PPV and PCV stimulated similar IgG levels and OPK at 4–8 weeks after vaccination. Six months after receipt of PPV, the antibody levels declined to baseline but remained modestly elevated after receipt of PCV. PCV administered 6 months after PPV stimulated modest increases in IgG level that failed to reach the peaks observed after receipt of PPV. In contrast, PPV administered 6 months after PCV caused dramatic increases in the levels of IgG and OPK for all polysaccharides at 4–8 weeks, consistent with a booster effect. Six months after receipt of the second vaccination, however, levels of IgG and OPK fell precipitously in all patients, approaching baseline levels. Conclusions. In these high-risk subjects who have recovered after treatment for pneumonia, the effect of PPV is short-lived; PCV stimulates a more prolonged response. The use of PPV as a booster following PCV causes early increases in antibody levels, but the level of IgG declines rapidly thereafter, consistent with induction of suppressor cells or tolerance. Protein vaccines may be needed for high-risk adults.

Page Thumbnails

  • Thumbnail: Page 
1019
    1019
  • Thumbnail: Page 
1020
    1020
  • Thumbnail: Page 
1021
    1021
  • Thumbnail: Page 
1022
    1022
  • Thumbnail: Page 
1023
    1023
  • Thumbnail: Page 
1024
    1024
  • Thumbnail: Page 
1025
    1025
  • Thumbnail: Page 
1026
    1026
  • Thumbnail: Page 
1027
    1027